
    due to cranial nerve palsies observed
  
['hepatitis b']
['antiviral therapy (tenofovir or entecavir)', 'birinapant', 'placebo (for birinapant)']

        Inclusion Criteria:

          -  Documented history of chronic Hepatitis B infection currently being treated with
             tenofovir or entecavir for at least 3 months

          -  Measurable titer of HBsAg

          -  HBV DNA level < 2 log copies/mL or 10² copies/mL

          -  No more than Child-Pugh score of 5 plus a valid FibroScan® of at least 10 readings
             with a median score of <7 and interquartile range of < 30%

          -  Adequate liver function, aspartate AST and ALT ≤2 x ULN

          -  Adequate renal function as evidenced by creatinine ≤2 mg/dL

        Exclusion Criteria:

          -  Participation in any interventional study within 4 weeks prior to Screening

          -  Known HIV infection, Hepatitis C, or other significant hepatic disorder including
             cirrhosis (Child-Pugh Class B or C)

          -  Serious illness or autoimmune disease or other known liver disease

          -  Uncontrolled hypertension

          -  Impaired cardiac function, uncontrolled cardiac arrhythmias despite medications, or
             clinically significant cardiac disease

          -  Currently breast feeding, pregnant or planning on becoming pregnant

          -  Known allergy or hypersensitivity to any of the formulation components of birinapant
             or placebo, including citric acid

          -  History of cranial nerve palsy

          -  Current treatment with anti-TNF therapies or has received treatment with anti-TNF
             therapies within the last 6 months

          -  Use of non-steroidal anti-inflammatory drugs
      